Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni(Medica (Italy)), Tadeusz Pieńkowski(Centrum Onkologii), Young‐Hyuck Im(Samsung Medical Center), Laslo Roman(Leningrad Regional Cancer Center), Ling‐Ming Tseng(Taipei Veterans General Hospital), Mei-Ching Liu(Koo Foundation Sun Yat-Sen Cancer Center), Aňa Lluch(Universitat de València), Elżbieta Starosławska(St. John's University), Juan de la Haba-Rodríguez(Hospital Universitario Reina Sofía), Seock‐Ah Im(Seoul National University Hospital), José Luiz Pedrini(Hospital Nossa Senhora da Conceição), Brigitte Poirier(Hôpital du Saint-Sacrement), Paolo Morandi(Ospedale San Bortolo), Semiglazov Vf(Institute of Oncology NN Petrov), Vichien Srimuninnimit(Siriraj Hospital), Giulia Bianchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Tania Szado, Jayantha Ratnayake(Roche (United Kingdom)), Graham Ross(Roche (United Kingdom)), Pinuccia Valagussa(Fondazione Michelangelo)
Cited by 2,349
Abstract
Related Papers
No related papers found
Powered by citation graph analysis